Health Management Center, Shandong Provincial Qianfoshan Hospital, The First Affiliated-Hospital of Shandong First Medical University, Jinan, China.
J Diabetes Investig. 2020 Mar;11(2):349-355. doi: 10.1111/jdi.13148. Epub 2019 Oct 3.
AIMS/INTRODUCTION: Asprosin is a novel secreted adipokine that is induced by fasting and promotes hepatic glucose release. In healthy humans, circulating asprosin shows circadian oscillation with an acute drop coinciding with the onset of eating. The present study investigated whether this circadian oscillation still exists in patients with type 2 diabetes mellitus.
We recruited 60 patients with type 2 diabetes mellitus and 60 individuals with normal glucose tolerance (NGT). All participants completed a 75-g oral glucose tolerance test. Fasting and 2-h postprandial serum asprosin concentrations were measured by the enzyme-linked immunosorbent assay method. Partial correlation coefficients were calculated to analyze the relationships between serum asprosin level and parameters of glucose metabolism. Multiple logistic regression analysis was used to determine the association of serum asprosin level with diabetes.
Both fasting and postprandial asprosin levels were significantly higher in patients with type 2 diabetes mellitus. The postprandial asprosin level was apparently lower than fasting asprosin level in individuals with NGT. The fasting asprosin level closely correlated with type 2 diabetes mellitus after multiple adjustment (odds ratio 2.329, P = 0.023). Asprosin correlated negatively with change in blood glucose (r = -0.502, P < 0.001) and change in C-peptide (r = -0.467, P < 0.001) in individuals with NGT, but not in type 2 diabetes mellitus patients.
Serum asprosin level decreased coinciding with the onset of the oral glucose tolerance test in individuals with NGT, whereas this circadian oscillation was disturbed in type 2 diabetes mellitus patients. The impaired response of asprosin to glucose fluctuation in type 2 diabetes mellitus patients might be one of the reasons for the onset of type 2 diabetes mellitus.
目的/引言：Asprosin 是一种新型分泌型脂肪因子，它由禁食诱导，并促进肝脏葡萄糖释放。在健康人群中，循环 asprosin 呈昼夜节律性波动，与进食开始时的急性下降相一致。本研究旨在探讨 2 型糖尿病患者是否仍存在这种昼夜节律性波动。
我们招募了 60 例 2 型糖尿病患者和 60 例糖耐量正常（NGT）个体。所有参与者完成了 75g 口服葡萄糖耐量试验。采用酶联免疫吸附试验法检测空腹和餐后 2 小时血清 asprosin 浓度。计算偏相关系数分析血清 asprosin 水平与糖代谢参数之间的关系。采用多元逻辑回归分析确定血清 asprosin 水平与糖尿病的关系。
2 型糖尿病患者空腹和餐后 asprosin 水平均显著升高。NGT 个体餐后 asprosin 水平明显低于空腹水平。在多重调整后，空腹 asprosin 水平与 2 型糖尿病密切相关（比值比 2.329，P=0.023）。在 NGT 个体中，asprosin 与血糖变化呈负相关（r=-0.502，P<0.001）和 C 肽变化（r=-0.467，P<0.001），但在 2 型糖尿病患者中无相关性。
NGT 个体口服葡萄糖耐量试验开始时，血清 asprosin 水平下降，而这种昼夜节律性波动在 2 型糖尿病患者中受到干扰。2 型糖尿病患者 asprosin 对血糖波动的反应受损可能是 2 型糖尿病发病的原因之一。
